Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.66 |
| ▸ | GSK3A | P49840 | 15/20 | 0.66 |
| ▸ | PRKCB | P05771 | 6/20 | 0.66 |
| ▸ | CDK4 | P11802 | 6/20 | 0.66 |
| ▸ | CDK2 | P24941 | 5/20 | 0.66 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.66 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.66 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.66 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.66 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.66 |
| ▸ | PRKCG | P05129 | 2/20 | 0.66 |
| ▸ | LCK | P06239 | 2/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.66 |
| ▸ | PIM1 | P11309 | 2/20 | 0.66 |
| ▸ | CLK2 | P49760 | 2/20 | 0.66 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.66 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21941676 | 0.94 | GSK3B (0.66) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577659 | 0.91 | GSK3B (0.80) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL29534407 | 0.91 | GSK3B (0.80) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL20439160 | 0.90 | GSK3B (0.54) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL20439086 | 0.90 | GSK3B (0.54) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577691 | 0.90 | GSK3B (0.67) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577594 | 0.90 | GSK3B (0.82) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21941247 | 0.90 | GSK3B (0.67) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577573 | 0.89 | GSK3B (0.71) | GSK3BGSK3APRKCBCDK4CDK2 | |
| SCHEMBL21577716 | 0.88 | GSK3B (0.68) | GSK3BGSK3APRKCBCDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259559-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | Frequency Therapeutics, Inc. | 2022-08-18 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2020210388-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020163814-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200121681-A1 | METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION | Frequency Therapeutics, Inc. | 2020-04-23 | — | — | US | disclosed |
| US-20200121681-A1 | METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION | Frequency Therapeutics, Inc. | 2020-04-23 | — | — | US | disclosed |
| US-20200113913-A1 | METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION | Frequency Therapeutics, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200080055-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING PI3K | UNITED STATES GOVERNMENT | 2020-03-12 | — | — | US | disclosed |
| US-20200080054-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | UNITED STATES GOVERNMENT | 2020-03-12 | — | — | US | disclosed |
| WO-2020037323-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | Frequency Therapeutics, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037323-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | Frequency Therapeutics, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20190352313-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | Frequency Therapeutics, Inc. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | GSK3B 92/4885GSK3A 152/4885PRKCB 373/4885 |
| US-20200113913-A1 | METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION | SHH, WNT3A, WNT1 | GSK3B 141/4885GSK3A 142/4885PRKCB 560/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | GSK3B 678/4885GSK3A 732/4885PRKCB 2425/4885 |
| US-20200080054-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | NOTCH1, HES1, NOTCH3 | GSK3B 1102/4885GSK3A 1348/4885PRKCB 197/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | GSK3B 42/4885GSK3A 24/4885PRKCB 790/4885 |
| US-20200121681-A1 | METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION | SHH, GLI1, WNT1 | GSK3B 152/4885GSK3A 147/4885PRKCB 563/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | GSK3B 63/4885GSK3A 66/4885PRKCB 252/4885 |
| US-20200080055-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING PI3K | PIK3C2B, PIK3CG, PIK3CB | GSK3B 47/4885GSK3A 62/4885PRKCB 46/4885 |
| US-20190352313-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | MCL1, PROX1, MKI67 | GSK3B 3641/4885GSK3A 3793/4885PRKCB 1923/4885 |
| US-20220259559-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | NOTCH1, HES1, NOTCH3 | GSK3B 1102/4885GSK3A 1348/4885PRKCB 197/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | GSK3B 2670/4885GSK3A 2714/4885PRKCB 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.